incy_Ex_10_2_2



		

			Exhibit 10.2.2

		


		

			CONFIDENTIAL TREATMENT MATERIAL

		





		
			 
		

		
			EXTENSION OF CONFIDENTIAL TREATMENT REQUESTED:  Certain identified information, marked by [***], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed.  An extension of confidential treatment for such information has been requested.  An unredacted version of this document has been filed separately with the Securities and Exchange Commission (the “Commission”).
		

		
			 
		

		
			THIRD AMENDMENT
		

		
			 
		

		
			This Third Amendment (“Third Amendment”) is entered into effective March 31, 2016 (the “Third Amendment Effective Date”) by and between Incyte Corporation (“Incyte”), a Delaware corporation having an office at 1801 Augustine Cut-off, Wilmington, DE 19803, and Eli Lilly and Company (“Lilly”), an Indiana corporation having an office at Lilly Corporate Center, Indianapolis, IN 46285.
		

		
			RECITALS
		

		
			A.   Incyte and Lilly are parties to (i) a License, Development and Commercialization Agreement, effective December 18, 2009, (ii) an Amendment, effective June 22, 2010, and (iii) a Second Amendment, effective August 1, 2011, pursuant to which Incyte has granted Lilly an exclusive License to develop and commercialize Licensed Compounds and Licensed Products in the Field (such Agreement, as so amended, the “Agreement”).
		

		
			 
		

		
			B.   The Parties now desire to further amend the Agreement by excluding Ruxolitinib (as defined below) for use in the Graft-Versus-Host Disease Field (as defined below) from the prohibition in Section 2.6 against Incyte Developing or Commercializing JAK2 Inhibitor Compounds in the Field in exchange for certain payments by Incyte and the waiver by Incyte of its Co-Promotion Option.
		

		
			 
		

		
			C.   Unless otherwise defined herein, all capitalized terms appearing in this Third Amendment shall have the meaning set forth in the Agreement.
		

		
			 
		

		
			NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:
		

		
			 
		

		
			1.    “Graft-Versus-Host Disease Field” means the treatment, control, management, mitigation, prevention or cure of all graft-versus-host disease Indications as defined in subsections 279.50 through 279.53 of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) as set forth in Exhibit A to this Third Amendment.  [***]
		

		
			 
		

		
			2.    “Ruxolitinib” means Incyte’s proprietary JAK2 Inhibitor known as ruxolitinib.
		

		
			 
		

		
			 
		

		
			


		 





		

			CONFIDENTIAL TREATMENT MATERIAL

		





		

		
			 
		

		
			3.    Section 2.6(a) (LICENSES; Non-Compete) and Section 2.6(b) (LICENSES; Non-Compete) of the Agreement shall not apply to Development or Commercialization of Ruxolitinib by Incyte, its Affiliates, licensees or sublicensees for use in the Graft-Versus-Host Disease Field.
		

		
			 
		

		
			4.    Incyte shall pay to Lilly the following payments:
		

		
			 
		

		
			a.    A one-time, non-creditable, non-refundable payment of $35,000,000 within [***];
		

		
			 
		

		
			b.    A one-time, non-creditable, non-refundable milestone payment of $20,000,000 within [***] after Incyte, [***] Regulatory Approval from the FDA of Ruxolitinib in the Graft-Versus-Host Disease Field; and
		

		
			 
		

		
			c.    A one-time, non-creditable, non-refundable milestone payment of [***].
		

		
			 
		

		
			5.    In no event may Lilly hold back any amount of any triggered and owing Lilly milestone or royalty payment under the Agreement as an escrow or otherwise in anticipation of any of the payments due and owing or to become due and owing from Incyte under this Third Amendment.  Similarly, in no event may Incyte hold back any amount of any triggered and owing Incyte upfront or milestone payment under this Third Amendment as an escrow or otherwise in anticipation of any of the payments due and owing or to become due and owing from Lilly under the Agreement.
		

		
			 
		

		
			6.    For clarity, the Parties acknowledge that the Graft-Versus-Host Disease Field is within the Inflammatory Disease Field and the Licensed Field, and that this Third Amendment does not alter this fact or restrict Lilly from Development or Commercialization of any Licensed Compound for use in the Graft-Versus-Host Disease Field.
		

		
			 
		

		
			7.    Section 5.4 (COMMERCIALIZATION; Co-Promotion) of the Agreement is hereby deleted and replaced in its entirety with “[RESERVED]”.  The Table of Contents of the Agreement is hereby appropriately revised to reflect such deletion, the reference to “Co-Promotion Option” in the “Additional Definitions” section of the Agreement is deleted, and Section 2.6(g)(iii) (LICENSES; Non-Compete) (relating to termination of the Co-Promotion Option)  of the Agreement is hereby deleted.
		

		
			 
		

		
			8.    The provision for notices to Incyte in Section 13.5 of the Agreement is hereby amended and restated to read in its entirety as follows:
		

		
			 
		

		
			“Notices to Incyte shall be addressed to:
		

		
			 
		

		
			Incyte Corporation
1801 Augustine Cut-Off
Wilmington, DE 19803
Attn: President and CEO
Facsimile No.: [***]
		

		
			
		

		
			


		 


		

			[***] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.     

		


		

			 

		








		

			CONFIDENTIAL TREATMENT MATERIAL

		





		

		
			 
		

		
			With a copy to:
		

		
			 
		

		
			Incyte Corporation
1801 Augustine Cut-Off
Wilmington, DE 19803
Attn: General Counsel
Facsimile No.: [***]”
		

		
			 
		

		
			9.    All other terms and conditions of the Agreement shall remain in full force and effect.
		

		
			 
		

		
			10.  Any disputes regarding this Third Amendment shall be dealt with in accordance the provisions of ARTICLE XII (Dispute Resolution) of the Agreement.  The provisions of ARTICLE XIII (Miscellaneous) of the Agreement shall apply to this Third Amendment as if repeated herein.
		

		
			 
		

		
			[remainder of page intentionally left blank]
		

		
			 
		

		
			 






		

		
			
		

		
			


		 


		

			[***] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.     

		


		

			 

		








		

			CONFIDENTIAL TREATMENT MATERIAL

		





		

		
			 
		

		
			 






		

		
			IN WITNESS WHEREOF, the parties by their respective authorized representatives have executed this Third Amendment as of the Effective Date.
		

			
					
						/s/ David A. Ricks

					
						Name: David A. Ricks

					
						Title: President, Lilly Bio-Medicines

					
						 

					
					
						 

					
					
						/s/ Hervé Hoppenot

					
						Name: Hervé Hoppenot

					
						 

					
						 

				
	
					
						ELI LILLY AND COMPANY

					
						By:     /s/ David A. Ricks

					
						           Name: David A. Ricks

					
						           Title: President, Lilly Bio-Medicines

					
					
						    

					
					
						INCYTE CORPORATION

					
						By:       /s/ Hervé Hoppenot

					
						Name: Hervé Hoppenot

					
						Title: President and Chief Executive Officer

				



		
			 
		

		
			
		

		
			


		 


		

			 

		


		

			 

		








		

			CONFIDENTIAL TREATMENT MATERIAL

		





		

		
			 
		

		
			Exhibit A
		

		
			 
		

		
			Graft-Versus-Host Disease Field (ICD-9-CM)
		

		
			 
		

		
			279.50 Graft-versus-host disease, unspecified (including prophylaxis of Graft-versus-host disease)
279.51 Acute graft-versus-host disease
279.52 Chronic graft-versus-host disease
279.53 Acute on chronic graft-versus-host disease